Tao Mengyu, Cheng Jiejun, Wu Xia
Department of Obstetrics & Gynecology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, People's Republic of China.
Shanghai Key Laboratory of Gynecologic Oncology, Shanghai 200127, People's Republic of China.
Onco Targets Ther. 2020 Dec 18;13:12979-12986. doi: 10.2147/OTT.S281302. eCollection 2020.
Brain metastases from epithelial ovarian cancer are very rare with an incidence of only 1-2.5%. Many therapeutic methods such as surgery, irradiation and chemotherapy do produce survival benefits, but the overall outcome remains unsatisfactory. The (breast cancer susceptibility gene) mutation status seems to be associated with the development of brain metastases from ovarian cancer and these patients may benefit from treatment with PARP (poly ADP ribose polymerase) inhibitors. Here is a case where a Chinese female patient diagnosed with high-grade serous ovarian cancer with brain metastases was detected to have known germline mutation and somatic mutation. The patient underwent whole brain radiotherapy and systemic chemotherapy, commenced niraparib as maintenance treatment and then presented considerable clinical and radiological response.
上皮性卵巢癌脑转移非常罕见，发生率仅为1%-2.5%。许多治疗方法，如手术、放疗和化疗确实能带来生存益处，但总体结果仍不尽人意。（乳腺癌易感基因）突变状态似乎与卵巢癌脑转移的发生有关，这些患者可能从聚（ADP-核糖）聚合酶（PARP）抑制剂治疗中获益。本文报道1例中国女性患者，诊断为高级别浆液性卵巢癌伴脑转移，检测发现存在已知的胚系突变和体细胞突变。该患者接受了全脑放疗和全身化疗，开始使用尼拉帕利作为维持治疗，随后出现了显著的临床和影像学反应。
